Yeah, I think I've had about enough over there for
Post# of 30028
Posted On: 08/11/2014 12:37:28 PM
Re: SouthBreeze #3584
Yeah, I think I've had about enough over there for the day.
I think we've started a new run today. The catalysts from Gerald's blog are looming over the stock now and will have a magnetic pull upwards on the pps. I say we get to the .15 cent to .18 cent range by August 22nd when we have the Q2 CC. If the LymPro Revenue Guidance is good, we will test .20 cents before September 1st.
After that the pull of the complete bridge data and partnership announcement could put us somewhere in the .20 to .25 cent range by the shareholder meeting in SF on September 22nd. (Which I think I'll go to by the way)
If the LymPro partner is Johnson & Johnson or Quest or someone of that quality and the terms of the partnership are impressive, we will test .40 cents before the end of September.
I don't know quite how to evaluate Eltoprazine's impact.
I know Gerald believes when we get back FDA Orphan Designation on Retinitis....he believes that will pop the pps upward because the indication becomes immediately "partnerable." When I asked him if a MANF partnership could be here in time to help us up list he said, "Don't count that out." I still see a Retinitis partnership in 2014 as remote, but possible. Nevertheless, it would juice up the looks of our portfolio that it would put the SI Swimsuit Edition to shame! Especially if we got Fast Track or Break Through designations!
So we have good things to look forward to from here. Flipping the stock at this point would be hazardous to your financial health.
I think we've started a new run today. The catalysts from Gerald's blog are looming over the stock now and will have a magnetic pull upwards on the pps. I say we get to the .15 cent to .18 cent range by August 22nd when we have the Q2 CC. If the LymPro Revenue Guidance is good, we will test .20 cents before September 1st.
After that the pull of the complete bridge data and partnership announcement could put us somewhere in the .20 to .25 cent range by the shareholder meeting in SF on September 22nd. (Which I think I'll go to by the way)
If the LymPro partner is Johnson & Johnson or Quest or someone of that quality and the terms of the partnership are impressive, we will test .40 cents before the end of September.
I don't know quite how to evaluate Eltoprazine's impact.
I know Gerald believes when we get back FDA Orphan Designation on Retinitis....he believes that will pop the pps upward because the indication becomes immediately "partnerable." When I asked him if a MANF partnership could be here in time to help us up list he said, "Don't count that out." I still see a Retinitis partnership in 2014 as remote, but possible. Nevertheless, it would juice up the looks of our portfolio that it would put the SI Swimsuit Edition to shame! Especially if we got Fast Track or Break Through designations!
So we have good things to look forward to from here. Flipping the stock at this point would be hazardous to your financial health.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼